SEC filing · 8-K

Aytu Biopharma, Inc: Quarterly results

Aytu BioPharma reported fourth quarter net revenue of $16.1 million and full year fiscal 2026 net revenue of $57.6 million.

Filed September 22, 2026

Mixed for the company

What happened

Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Aytu Biopharma, Inc

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.